About
Steven A. Elms has been a director of ADMA since 2007 and serves as Chairman of the Board. He is a Managing Partner at Aisling Capital, which he joined in 2000.
He was previously a Principal in the Life Sciences Investment Banking Group of Hambrecht & Quist, where over five years he was involved in more than 60 financing and M&A transactions, and earlier traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. He received a B.A. in Human Biology from Stanford University and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
Roles
Adma Biologics, Inc.
Chairman of the Board · Current role
2007–present
Hambrecht & Quist
Principal, Life Sciences Investment Banking Group · Involved in over 60 financing and M&A transactions over roughly five years.
—
Donaldson, Lufkin & Jenrette
Mortgage-backed securities trader
—
External Roles
Aisling Capital
Managing Partner
—
Elevation Oncology (Nasdaq: ELEV)
Board of Directors
—
Marker Therapeutics (Nasdaq: MRKR)
Board of Directors
—
Treeline Biosciences
Board of Directors
—
Marker Therapeutics
Board of Directors
—
Director Compensation
FY 2025Fees earned or paid in cash
$96,250
Stock awards (RSUs)
$174,986
10,889 RSUs granted 2/19/2025
Option awards
$174,999
16,279 options, $16.07 exercise price
Also at Adma Biologics, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.